Supernus announces issuance of first use patents for SPN-812 Supernus Pharmaceuticals announced the issuance of a European patent and Canadian patent for SPN-812, its novel non-stimulant product candidate for the treatment of ADHD. These patents will provide protection for the product with expiration that is no earlier than 2029. Supernus has several additional patent applications for SPN-812 pending in other geographic regions, including the United States.
News For SUPN From The Last 14 Days
Check below for free stories on SUPN the last two weeks.
Supernus to explore 'broad range of strategic opportunities' Supernus Pharmaceuticals is providing the following business update in light of recent investor filings with the SEC: "The company will explore a broad range of strategic opportunities. This includes in-licensing products and entering into co-promotion partnerships which are synergistic with our neurology sales force call point, potential co-development partnerships on our pipeline products, and growth opportunities through value-creating and transformative merger and acquisition transactions."